As ATX has emerged as a therapeutic target in idiopathic pulmonary fibrosis (IPF) [12], many novel compounds are increasingly reported [37] and will be likely soon commercially available, thus allowing pharmacologic studies in vivo. Here, ENPP2 is linked to idiopathic pulmonary fibrosis.